Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;22(6):764-765.
doi: 10.1016/S1473-3099(22)00295-X.

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

Florence Ader  1 , Maude Bouscambert-Duchamp  2 , Maya Hites  3 , Nathan Peiffer-Smadja  4 , France Mentré  5 , Charles Burdet  5 ; DisCoVeRy Study Group
Collaborators, Affiliations

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

Florence Ader et al. Lancet Infect Dis. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

FM reports grants from INSERM Reacting (French Government), the Ministry of Health (French Government), and the European Commission, during the conduct of the study, and grants from Sanofi and Roche, unrelated to this Correspondence. MH reports grants from The Belgian Center for Knowledge and Fonds Erasme-COVID-ULB, during the conduct of the study, and personal fees from Gilead, unrelated to this Correspondence. CB reports personal fees from Da Volterra and Mylan Pharmaceuticals, unrelated to this Correspondence. All other authors declare no competing interests. This study received funding from the EU's Horizon 2020 Research and Innovation Programme, Austrian Group Medical Tumor, Belgian Health Care Knowledge Centre, Fonds Erasme-COVID-Université Libre de Bruxelles, Inserm REACTing network, the French Ministry of Health, Paris Ile-de-France Region, European Regional Development Fund, Portugal Ministry of Health, Portugal Agency for Clinical Research and Biomedical Innovation, European Union Commission, and Domaine d’intérêt majeur One Health Île-de-France. Remdesivir was provided by Gilead free of charge. FM and CB are joint last authors. Members of the DisCoVeRy Study Group are listed in the appendix.

Figures

Figure
Figure
Clinical status at day 15 of patients included in the intention-to-treat population As measured by the 7-point ordinal scale. Reported numbers refer to the proportion of patients with the corresponding level in each group. The intention-to-treat population included all participants with a positive SARS-CoV-2 PCR test obtained in the past 9 days who were randomly assigned to a treatment group, for whom a valid consent form was obtained and who did not receive any investigational treatment in the past 29 days. ECMO=extracorporeal membrane oxygenation.
See this image and copyright information in PMC

References

    1. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22:209–221. - PMC - PubMed
    1. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial. medRxiv. 2022 doi: 10.1101/2022.03.30.22273206. published online April 12. (preprint). - DOI

MeSH terms